Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | hexokinase | 0.2593 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase | 0.2593 | 1 | 1 |
Toxoplasma gondii | hexokinase | 0.2593 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase | 0.2593 | 1 | 1 |
Treponema pallidum | hexokinase (hxk) | 0.2593 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.2593 | 1 | 0.5 |
Onchocerca volvulus | 0.2593 | 1 | 1 | |
Plasmodium vivax | hexokinase, putative | 0.2593 | 1 | 0.5 |
Leishmania major | hexokinase, putative | 0.2593 | 1 | 0.5 |
Onchocerca volvulus | 0.2593 | 1 | 1 | |
Plasmodium falciparum | hexokinase | 0.2593 | 1 | 0.5 |
Entamoeba histolytica | hexokinase 1 | 0.2593 | 1 | 0.5 |
Brugia malayi | Hexokinase family protein | 0.2593 | 1 | 1 |
Schistosoma mansoni | hexokinase | 0.2593 | 1 | 0.5 |
Trypanosoma cruzi | hexokinase, putative | 0.2593 | 1 | 0.5 |
Trypanosoma cruzi | hexokinase, putative | 0.2593 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase type 2 | 0.2593 | 1 | 0.5 |
Entamoeba histolytica | hexokinase 2 | 0.2593 | 1 | 0.5 |
Leishmania major | hexokinase, putative | 0.2593 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase type II | 0.2593 | 1 | 1 |
Trypanosoma brucei | hexokinase, putative | 0.2593 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.1768 | 0.1468 | 0.1468 |
Onchocerca volvulus | 0.2593 | 1 | 1 | |
Echinococcus multilocularis | hexokinase | 0.2593 | 1 | 0.5 |
Echinococcus granulosus | hexokinase | 0.2593 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.2593 | 1 | 0.5 |
Echinococcus granulosus | hexokinase | 0.2593 | 1 | 0.5 |
Echinococcus granulosus | hexokinase | 0.2593 | 1 | 0.5 |
Trypanosoma brucei | hexokinase | 0.2593 | 1 | 0.5 |
Echinococcus granulosus | hexokinase type 2 | 0.2593 | 1 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.